Anthem Biosciences IPO: Key Details for Investors to Know Before Subscription

Anthem Biosciences, a Contract Research, Development, and Manufacturing Organisation (CRDMO), is opening its Rs 3,395 crore public offering for subscription today, July 14. The IPO is an offer-for-sale, with a price band of Rs 540 to Rs 570 per share. The issue comprises 5.96 crore equity shares being sold by promoters and existing shareholders. The allotment of shares is expected to be finalised on July 17, and the shares are scheduled to be listed on July 21. The grey market is indicating a potential listing price of around Rs 670, a gain of nearly 17.5%.

Anthem Biosciences, a leading Contract Research, Development, and Manufacturing Organisation (CRDMO), has opened its Rs 3,395 crore Initial Public Offering (IPO) for subscription today, July 14. The IPO is an offer-for-sale (OFS), with a price band of Rs 540 to Rs 570 per share. The issue comprises 5.96 crore equity shares being sold by promoters and existing shareholders [1].

The IPO will be open for subscription from July 14 to July 16, with the allotment of shares expected to be finalised on July 17. The shares are scheduled to be listed on the BSE and NSE on July 21 [2]. The grey market is indicating a potential listing price of around Rs 670, which would represent a gain of nearly 17.5% [3].

Anthem Biosciences offers a comprehensive range of CRDMO services across various modalities and manufacturing techniques, including RNAi, ADC, peptides, lipids, and oligonucleotides. The company also manufactures and sells complex specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars [1].

The company's revenue from operations increased by 30% to Rs 1,844 crore in FY25 from Rs 1,419 crore in FY24. The PAT for the year ended March 31, 2025, was Rs 451 crore, a jump of 22.86% over FY24 [1].

The company has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025 [1]. The company is also in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL and constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned subsidiary) with an additional 25 kL custom synthesis capacity and 40 kL fermentation capacity, expected to be fully operational by the first half of Fiscal 2026 [1].

The grey market is indicating a potential listing price of around Rs 670, which would represent a gain of nearly 17.5% [3].

References:
[1] https://economictimes.indiatimes.com/markets/ipos/fpos/anthem-biosciences-ipo-rs-3395-crore-ipo-to-open-on-july-14/articleshow/122321114.cms
[2] https://indianexpress.com/article/business/market/anthem-biosciences-ipo-subscription-opens-on-july-14-check-price-band-10123653/
[3] https://economictimes.indiatimes.com/markets/ipos/fpos/anthem-biosciences-sets-ipo-price-band-at-rs-530-570/share/articleshow/122333703.cms